Complete financial analysis of Cannara Biotech Inc. (LOVFF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cannara Biotech Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Neto M.E Holdings Ltd (NTO.TA) Income Statement Analysis – Financial Results
- Bubs Australia Limited (BUB.AX) Income Statement Analysis – Financial Results
- Kingfa Science & Technology (India) Limited (KINGFA.NS) Income Statement Analysis – Financial Results
- Lux Industries Limited (LUXIND.NS) Income Statement Analysis – Financial Results
- Grupe, S.A.B. de C.V. (CIDMEGA.MX) Income Statement Analysis – Financial Results
Cannara Biotech Inc. (LOVFF)
About Cannara Biotech Inc.
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivated products in Canada. It also offers hemp-based CBD products through e-commerce platform. The company was incorporated in 2017 and is headquartered in Saint-Laurent, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | 81.75M | 57.26M | 35.84M | 17.02M | 2.55M | 2.10M | 432.64K |
| Cost of Revenue | 51.96M | 30.03M | 18.51M | 6.72M | 1.33M | 403.90K | 273.58K |
| Gross Profit | 29.79M | 27.23M | 17.33M | 10.30M | 1.22M | 1.69M | 159.06K |
| Gross Profit Ratio | 36.44% | 47.56% | 48.36% | 60.50% | 48.00% | 80.74% | 36.76% |
| Research & Development | 1.12M | 1.03M | 1.26M | 1.91M | 2.60M | 0.00 | 0.00 |
| General & Administrative | 12.97M | 10.61M | 8.59M | 6.16M | 8.06M | 10.58M | 1.60M |
| Selling & Marketing | 6.68M | 2.91M | 1.44M | 1.14M | 904.66K | 765.93K | 271.35K |
| SG&A | 19.65M | 13.52M | 10.03M | 7.30M | 8.97M | 11.35M | 1.87M |
| Other Expenses | -1.06M | 792.03K | 0.00 | 24.44K | 25.89K | 0.00 | 0.00 |
| Operating Expenses | 19.71M | 15.34M | 12.36M | 10.00M | 13.15M | 11.92M | 1.98M |
| Cost & Expenses | 71.67M | 45.37M | 30.87M | 16.72M | 14.48M | 12.32M | 2.25M |
| Interest Income | 178.96K | 0.00 | 92.69K | 52.79K | 265.77K | 679.62K | 27.09K |
| Interest Expense | 4.33M | 4.29M | 1.92M | 1.57M | 1.33M | 1.51M | 319.93K |
| Depreciation & Amortization | 6.35M | 4.94M | 3.92M | 3.03M | 2.58M | 566.33K | 109.68K |
| EBITDA | 15.16M | 15.77M | 8.40M | 3.06M | -9.19M | -10.89M | -1.68M |
| EBITDA Ratio | 18.55% | 27.54% | 21.18% | 18.91% | -357.47% | -428.81% | -389.08% |
| Operating Income | 10.08M | 11.89M | 4.94M | 257.28K | -11.95M | -10.22M | -1.82M |
| Operating Income Ratio | 12.33% | 20.76% | 13.78% | 1.51% | -468.56% | -487.52% | -420.01% |
| Total Other Income/Expenses | -5.59M | -4.94M | -2.64M | -1.79M | -1.14M | -2.75M | -295.77K |
| Income Before Tax | 4.48M | 6.95M | 2.31M | -1.53M | -13.09M | -12.97M | -2.11M |
| Income Before Tax Ratio | 5.49% | 12.13% | 6.43% | -8.98% | -513.33% | -618.60% | -488.38% |
| Income Tax Expense | -1.95M | 0.00 | 1.92M | 1.57M | 713.90K | 855.93K | 24.17K |
| Net Income | 6.44M | 6.95M | 2.31M | -1.53M | -12.48M | -12.32M | -2.11M |
| Net Income Ratio | 7.88% | 12.13% | 6.43% | -8.98% | -489.35% | -587.28% | -488.38% |
| EPS | 0.00 | 0.08 | 0.03 | -0.02 | -0.17 | -0.17 | -0.03 |
| EPS Diluted | 0.00 | 0.08 | 0.03 | -0.02 | -0.17 | -0.17 | -0.03 |
| Weighted Avg Shares Out | 0.00 | 89.30M | 87.67M | 76.52M | 71.33M | 70.68M | 69.38M |
| Weighted Avg Shares Out (Dil) | 0.00 | 89.30M | 87.84M | 76.52M | 71.33M | 70.68M | 69.38M |
Cannara Biotech Inc. Reports Q4 and Fiscal Year 2024 Results: Achieves Record Sales Growth and Operating Cash Flow, Solidifying Leadership in Canada's Cannabis Market
Record Q4 and year-end total revenues of $23.4 million and $82.2 million, representing a 28% and 43% increase compared to the same periods in 2023. Robust growth in Q4 over Q3 2024, with total revenues increasing by 20%, operating income by 42%,...
Cannara Biotech Reports Q3 2024 Financial Results
Net revenues up 22.6% to $19.5M, positive Adjusted EBITDA of $2.8M and operating cash flows of $4.3 million. Focused on the Canadian Cannabis Opportunity
Cannara Biotech Reports Q2 2024 Financial Results
Net revenue, increased to $19.7 million in Q2 2024 from $13.0 million in Q2 2023, a 51.0% increase. Gross profit, before fair value adjustments, increased to $7.1 million in Q2 2024 from $4.0 million in Q2 2023, a 77.2% increase.
Cannara Biotech Announces Record-Breaking Q1 2024 Results: Continued Robust Growth and Market Expansion
Record Q1 net revenues of $19.5 million, representing an 89% increase compared to the $10.3 million of net revenues generated in Q1 2023 Q1 operating income of $3.4 million, representing an 201% increase compared to the $1.1 million of operating...
Cannara Biotech Announces Engagement of Market Maker Services from Independent Trading Group ("ITG")
MONTREAL , Jan. 8, 2024 /PRNewswire/ - Cannara Biotech Inc. ("Cannara" or the "Company") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices with two mega facilities based in...
The 7 Most Undervalued Cannabis Stocks to Buy in December
Given that cannabis legalization is considered a growth trend, you may assume that there are few (if any) undervalued cannabis stocks. However, whether we're talking about undervalued in the traditional sense of the term, or undervalued using other metrics, there...
Cannara Biotech Announces Notice Of Annual General Meeting Of Shareholders To Be Held Virtually On January 25th, 2024
MONTREAL , Dec. 13, 2023 /PRNewswire/ - Cannara Biotech Inc. ("Cannara" or the "Company") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices with two mega facilities based in...
Cannara Biotech to Host Investor Webcast on Thursday December 14th, 2023
MONTREAL , Dec. 11, 2023 /PRNewswire/ - Cannara Biotech Inc. ("Cannara" or the "Company") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative products with one of the largest indoor cannabis cultivation facilities in Canada, and...
Cannara Biotech Reports Fourth Quarter and 2023 Fiscal Year Results: Record Growth and Profitability Continues
Record Q4 and year end net revenues of $18.3 million and $57.6 million, representing a 53% and 60% increase compared to the same periods of 2022 Sequentially, Q4 showed significant growth over Q3 2023 with higher net revenues by 15%,...
7 Smoking-Hot 420 Stocks to Buy in 2023
Sentiment for the cannabis sector has yet to rebound from its last peak in late 2020/early 2021, but that doesn't mean you need to skip out on 420 stocks. Even Forbes recently argued that full U.S. legalization of marijuana remains (at least) a...
Source: https://incomestatements.info
Category: Stock Reports